| Market Cap | 158.93M |
| Revenue (ttm) | 11.86M |
| Net Income (ttm) | -31.96M |
| Shares Out | 30.05M |
| EPS (ttm) | -1.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70,339 |
| Open | 5.31 |
| Previous Close | 5.33 |
| Day's Range | 5.16 - 5.45 |
| 52-Week Range | 3.90 - 11.42 |
| Beta | 0.26 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+117.8%) |
| Earnings Date | May 8, 2025 |
About PROF
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prosta... [Read more]
Financial Performance
In 2024, Profound Medical's revenue was $10.68 million, an increase of 48.35% compared to the previous year's $7.20 million. Losses were -$27.82 million, -1.79% less than in 2023.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for PROF stock is "Strong Buy." The 12-month stock price forecast is $11.5, which is an increase of 117.80% from the latest price.
News
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Me...
Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript
Profound Medical Corporation (NASDAQ:PROF) Q1 2025 - Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Stephen Kilmer - Head IR Rashed Dewan - CFO Dr. Mathieu Burtnyk - COO Tom Tam...
Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizabl...
Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy
– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and m...
Profound Medical AUA 2025 Investor Event Agenda
TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizabl...
Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (N...
PROF Investors Have Opportunity to Join Profound Medical Corp. Fraud Investigation with the Schall Law Firm
LOS ANGELES , April 8, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Profound Medical Cor...
Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (N...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (N...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (N...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (N...
Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (N...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Investors to Connect
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (N...
Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...
Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...
Wolf Haldenstein Adler Freeman & Herz LLP is investigating Profound Medical Corp. for potential violations of securities laws
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. ("Profound" or "the Company") (...
Profound Medical Corporation (PROF) Q4 2024 Earnings Conference Call Transcript
Profound Medical Corporation (NASDAQ:PROF) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Stephen Kilmer – IR Rashed Dewan - CFO Mathieu Burtnyk - COO Tom Tamberrino -...
Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow
TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues
– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds...
Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...
Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares
TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of its previously announced underwritten public off...